• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Pemafibrate does not lower cardiovascular risk in individuals with hypertriglyceridemia

byNhat Hung (Benjamin) LamandKiera Liblik
December 2, 2022
in Cardiology, Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with type 2 diabetes and hypertriglyceridemia, pemafibrate did not alter the incidence of cardiovascular events compared to placebo.

2. Pemafibrate was associated with higher rates of adverse renal events, venous thromboembolism, and a lower rate of non-alcoholic fatty liver disease as compared to placebo control.  

Evidence Rating Level: 1 (Excellent)

Study Rundown: Increased triglyceride levels, especially in the context of low high-density lipoprotein (HDL) cholesterol and concomitant type 2 diabetes, are associated with a higher risk of adverse cardiovascular events. Nevertheless, evidence for the impact of triglyceride-lowering therapies on cardiovascular risk has been equivocal. Pemafibrate is a triglyceride-lowering and HDL cholesterol-raising drug which works by modulating peroxisome proliferator-activated receptor α. The current study was a multi-national randomized controlled trial evaluating the effects of pemafibrate on cardiovascular risk among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, and low HDL cholesterol. At the median follow-up of 3.4 years, pemafibrate was associated with significantly reduced triglyceride, very-low-density lipoprotein (VLDL) cholesterol, remnant cholesterol, and apolipoprotein C-III levels. Nevertheless, pemafibrate use had no impact on the risk of cardiovascular events. Consistent with the specific mechanism via which pemafibrate exerts its triglyceride-lowering effects, the trial results demonstrated that the drug did not alter the risk of adverse cardiovascular adverse events in the study participants, despite favorable changes in lipid profiles.

Click here to read the study in NEJM

In-Depth [randomized controlled trial]: The current study was a multinational, double-blind, randomized, controlled trial to investigate the impact of pemafibrate on cardiovascular risk in patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, low HDL cholesterol, and well-controlled low-density lipoprotein (LDL) cholesterol levels. Patients were eligible for the primary-prevention cohort if they were at 50 (male) or 55 (female) years of age and older and did not have atherosclerotic cardiovascular disease. Those in the secondary-prevention cohort were 18 years of age or older and had atherosclerotic cardiovascular disease. The primary outcome was the first occurrence of a major adverse cardiovascular event, defined as a composite of myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes. Overall, 10,497 patients were randomized to receive pemafibrate (0.2mg twice daily) or placebo and followed for a median period of 3.4 years. It was observed that by four months, pemafibrate use was associated with reduced levels of triglycerides, VLDL cholesterol, remnant cholesterol, and apolipoprotein C-III, as well as increased levels of LDL cholesterol and apolipoprotein B. The primary composite outcome occurred in 572 patients in the pemafibrate group and 560 patients in the placebo group (Hazard Ratio, 1.03; 95% Confidence Interval, 0.91 to 1.15), with no differences observed in subgroups such as within the primary-prevention cohort, and at different statin intensities. Serious adverse events occurred at similar rates across the two groups. Pemafibrate was associated with higher rates of adverse renal events and venous thromboembolism and a lower rate of non-alcoholic fatty liver disease. Overall, these results showed that in patients with type 2 diabetes, hypertriglyceridemia, low HDL cholesterol, and well-controlled LDL cholesterol, pemafibrate alone did not reduce cardiovascular risks despite having intended effects on lipid biomarkers.

Image: PD

RELATED REPORTS

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis

#VisualAbstract: Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: atherosclerosiscardiologycardiovascular riskchronic diseasefibratehypertriglyceridemiapemafibratetype 2 diabetes
Previous Post

Religion and spirituality dimensions may be beneficial in bipolar disorder symptoms

Next Post

No difference in clinical outcomes between joint replacement and fusion surgeries for ankle osteoarthritis

RelatedReports

Intravenous contrast may not increase risk of acute kidney injury
Chronic Disease

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

February 3, 2023
Physical therapy reduces pain in adults with knee osteoarthritis
Chronic Disease

High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis

February 3, 2023
#VisualAbstract: Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
StudyGraphics

#VisualAbstract: Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

February 3, 2023
Nonleg venous thromboses associated with PE, longer ICU stay
Chronic Disease

Efanesoctocog alfa is efficacious in treating severe hemophilia A

February 2, 2023
Next Post
Patient Basics: Ankle Fracture

No difference in clinical outcomes between joint replacement and fusion surgeries for ankle osteoarthritis

Cardiovascular risk factors related to brain volume and associated dementia

Autoimmune encephalitis misdiagnosis in adults can lead to harm

Paternal factors associated with short interpregnancy interval

2 Minute Medicine Rewind December 5, 2022

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options